ACRIN 6698/I-SPY2 Breast DWI

The American College of Radiology Imaging Network (ACRIN) trial 6698 was a multi-center study to evaluate the effectiveness of quantitative diffusion weighted imaging (DWI) for assessing breast cancer response to neoadjuvant chemotherapy (NAC). ACRIN 6698 was performed as a sub-study of the ongoing I-SPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2), an adaptive, multi-agent phase II trial designed to quickly identify new agents for breast cancer. This collection includes serial MRI studies with DWI, DCE and T2w acquisitions on women undergoing NAC for invasive breast cancer, with single-visit test/retest DWI acquisitions on a subset of the trial subjects.

美国放射学院影像网络（ACRIN）试验6698是一项多中心研究，旨在评估定量弥散加权成像（diffusion weighted imaging, DWI）用于评价浸润性乳腺癌对新辅助化疗（neoadjuvant chemotherapy, NAC）治疗应答的效果。ACRIN 6698作为正在进行的I-SPY 2试验（Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2）的子研究开展，该试验为自适应多药物II期临床试验，其设计目标是快速筛选针对乳腺癌的新型治疗药物。本数据集收录了罹患浸润性乳腺癌并接受新辅助化疗的女性患者的系列磁共振成像研究数据，包含弥散加权成像（DWI）、动态对比增强成像（dynamic contrast-enhanced, DCE）及T2加权成像（T2w）采集序列；此外还收录了该试验部分受试者的单次就诊重复测试DWI采集数据。

搜集汇总

背景与挑战

背景概述

该数据集来自ACRIN 6698/I-SPY2试验，是一个多中心研究，旨在评估定量扩散加权成像（DWI）对乳腺癌新辅助化疗反应的评估效果。作为I-SPY 2试验的子研究，它包含接受治疗女性的系列MRI数据（DWI、DCE和T2w采集），以及部分受试者的测试/重测DWI数据，专注于乳腺癌治疗反应的影像学分析。